NO314126B1 - Farmasöytisk preparat i gelform for behandling av hudsykdommer og for desinfisering av huden, samt anvendelse av en kombinasjon av et polymer-geldannelsesmiddels og en lavere alkanol ved fremstilling av et preparat oganvendelse av enlavere alk - Google Patents
Farmasöytisk preparat i gelform for behandling av hudsykdommer og for desinfisering av huden, samt anvendelse av en kombinasjon av et polymer-geldannelsesmiddels og en lavere alkanol ved fremstilling av et preparat oganvendelse av enlavere alk Download PDFInfo
- Publication number
- NO314126B1 NO314126B1 NO19963971A NO963971A NO314126B1 NO 314126 B1 NO314126 B1 NO 314126B1 NO 19963971 A NO19963971 A NO 19963971A NO 963971 A NO963971 A NO 963971A NO 314126 B1 NO314126 B1 NO 314126B1
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- skin
- gel
- treatment
- weight
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 44
- 239000003349 gelling agent Substances 0.000 title claims abstract description 30
- 208000017520 skin disease Diseases 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 75
- 238000004659 sterilization and disinfection Methods 0.000 title description 6
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 91
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 210000003491 skin Anatomy 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 229920000896 Ethulose Polymers 0.000 claims description 20
- 229920000642 polymer Polymers 0.000 claims description 17
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 16
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 16
- 241000700584 Simplexvirus Species 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229920002678 cellulose Polymers 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229920003086 cellulose ether Polymers 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 210000000434 stratum corneum Anatomy 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 244000078703 ectoparasite Species 0.000 claims description 2
- 238000001035 drying Methods 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 239000011159 matrix material Substances 0.000 abstract description 7
- 239000000654 additive Substances 0.000 abstract description 6
- 238000001704 evaporation Methods 0.000 abstract description 6
- 230000008020 evaporation Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000005923 long-lasting effect Effects 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 87
- 208000015181 infectious disease Diseases 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 244000045947 parasite Species 0.000 description 10
- 206010040872 skin infection Diseases 0.000 description 10
- 229920002125 Sokalan® Polymers 0.000 description 9
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 208000009889 Herpes Simplex Diseases 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 239000000739 antihistaminic agent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000011505 plaster Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 208000003322 Coinfection Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 229940125715 antihistaminic agent Drugs 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000645 desinfectant Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 206010003402 Arthropod sting Diseases 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 241000238876 Acari Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 201000006082 Chickenpox Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000001688 Herpes Genitalis Diseases 0.000 description 3
- 206010046980 Varicella Diseases 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 201000004946 genital herpes Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 231100000046 skin rash Toxicity 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 208000003014 Bites and Stings Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 206010019973 Herpes virus infection Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 206010065173 Viral skin infection Diseases 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000022535 Infectious Skin disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000509427 Sarcoptes scabiei Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- -1 ethoxy-2-ethoxyethyleneoxy Chemical group 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- ZBJVLWIYKOAYQH-UHFFFAOYSA-N naphthalen-2-yl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=C(C=CC=C2)C2=C1 ZBJVLWIYKOAYQH-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical class [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Pest Control & Pesticides (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK32594 | 1994-03-21 | ||
| PCT/EP1995/001025 WO1995025544A1 (en) | 1994-03-21 | 1995-03-20 | Gel for treatment of skin diseases and for disinfection of the skin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO963971D0 NO963971D0 (no) | 1996-09-20 |
| NO963971L NO963971L (no) | 1996-11-19 |
| NO314126B1 true NO314126B1 (no) | 2003-02-03 |
Family
ID=8092278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19963971A NO314126B1 (no) | 1994-03-21 | 1996-09-20 | Farmasöytisk preparat i gelform for behandling av hudsykdommer og for desinfisering av huden, samt anvendelse av en kombinasjon av et polymer-geldannelsesmiddels og en lavere alkanol ved fremstilling av et preparat oganvendelse av enlavere alk |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US5981605A (de) |
| EP (1) | EP0751789B1 (de) |
| JP (1) | JP3560977B2 (de) |
| KR (1) | KR100396278B1 (de) |
| CN (1) | CN1146725A (de) |
| AT (1) | ATE208212T1 (de) |
| AU (1) | AU701872B2 (de) |
| BR (1) | BR9507164A (de) |
| CA (1) | CA2186045A1 (de) |
| CZ (2) | CZ286758B6 (de) |
| DE (1) | DE69523745T2 (de) |
| DK (1) | DK0751789T3 (de) |
| EE (1) | EE03293B1 (de) |
| ES (1) | ES2168111T3 (de) |
| FI (1) | FI963696A (de) |
| HU (1) | HUP9774641A2 (de) |
| LV (1) | LV12951B (de) |
| MX (1) | MX9604208A (de) |
| NO (1) | NO314126B1 (de) |
| NZ (1) | NZ283135A (de) |
| PL (1) | PL179918B1 (de) |
| PT (1) | PT751789E (de) |
| RU (1) | RU2142273C1 (de) |
| SK (1) | SK281575B6 (de) |
| UA (1) | UA41989C2 (de) |
| WO (1) | WO1995025544A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT751789E (pt) * | 1994-03-21 | 2002-04-29 | Aase Brown Thomsen | Gel para o tratamento de doencas da pele e para desinfeccao da pele |
| US6416760B2 (en) * | 1995-01-26 | 2002-07-09 | Societe L'oreal | Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin |
| FR2732221B1 (fr) * | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
| DE19624508A1 (de) * | 1996-06-19 | 1998-01-08 | Guetter Hans Peter Dr | Verwendung von C¶3¶-C¶4¶-Alkoholen zur Behandlung von Herpeserkrankungen |
| CA2265774C (en) | 1996-06-24 | 2009-05-05 | Bio-Safe Enterprises, Inc. | Antibacterial composition |
| US7767216B2 (en) * | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6759434B2 (en) | 1999-09-22 | 2004-07-06 | B. Ron Johnson | Anti-infective compositions, methods and systems for treating disordered tissue |
| US8173709B2 (en) * | 1999-09-22 | 2012-05-08 | Quadex Pharmaceuticals, Llc | Anti-infective methods for treating pathogen-induced disordered tissues |
| EP1295893A4 (de) * | 2000-05-31 | 2005-10-26 | Japan Science & Tech Agency | Ginsenoside zur förderung der hautgeweberegeneration |
| AUPR028000A0 (en) * | 2000-09-21 | 2000-10-12 | Hair Advisory Centre Pty. Ltd. | Ectoparasite formulation |
| US6581775B1 (en) * | 2001-08-10 | 2003-06-24 | Garo Hagopian | Method of external genital cleansing and prophylactic kit |
| NZ532944A (en) * | 2001-10-16 | 2005-10-28 | Avanir Pharmaceuticals | Stable, topical formulation for treating viral and inflammatory conditions comprising 10% n-docosanol, 5% of a stearate, 8% mineral oil, 5% propylene glycol, 2.7% benzyl alcohol and water |
| US20050042240A1 (en) * | 2002-01-28 | 2005-02-24 | Utterberg David S. | High viscosity antibacterials |
| DE10219597A1 (de) * | 2002-05-02 | 2003-11-20 | Wella Ag | Wasserfreie Haarstylinggele |
| AU2003242235A1 (en) * | 2002-06-18 | 2003-12-31 | Pola Chemical Industries Inc. | Antifungal medicinal composition |
| US20040191286A1 (en) * | 2003-03-24 | 2004-09-30 | Bijan Safai | Head lice medication and treatment |
| GB0318160D0 (en) * | 2003-08-02 | 2003-09-03 | Ssl Int Plc | Parasiticidal composition |
| US8741332B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
| US8741333B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
| US8907153B2 (en) | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
| US20070196453A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs |
| US20060024372A1 (en) * | 2004-07-29 | 2006-02-02 | Utterberg David S | High viscosity antibacterials |
| US7268165B2 (en) * | 2004-08-20 | 2007-09-11 | Steris Inc. | Enhanced activity alcohol-based antimicrobial compositions |
| US20070116749A1 (en) * | 2005-11-21 | 2007-05-24 | Grossman Leonard D | Method for treatment of cellulitis |
| DE102005059742A1 (de) | 2005-12-13 | 2007-06-14 | Beiersdorf Ag | Transparentes Sonnenschutzmittel |
| AU2007275581B2 (en) | 2006-07-21 | 2011-09-08 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
| AU2006349528B2 (en) | 2006-10-23 | 2012-06-07 | Ecolab Inc. | Virucidal composition |
| EP2097074A4 (de) * | 2006-12-04 | 2013-05-01 | Glaxosmithkline Llc | Pharmazeutische topische zusammensetzungen |
| JP5028131B2 (ja) * | 2007-04-13 | 2012-09-19 | 花王株式会社 | ゲル化剤 |
| EP2152304B1 (de) | 2007-05-02 | 2018-08-22 | The Regents of the University of Michigan | Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür |
| WO2008153748A1 (en) * | 2007-05-24 | 2008-12-18 | The Mclean Hospital Corporation | Methods and compositions for the use of sargassum fusiforme for the inhibition of hiv-1 infection |
| DE102008028993A1 (de) * | 2007-06-29 | 2009-01-08 | Bode Chemie Gmbh & Co. Kg | Verwendung eines alkoholischen Desinfektionsmittels zur Schnelldesinfektion |
| EA013233B1 (ru) * | 2008-06-12 | 2010-04-30 | Иностранное Частное Унитарное Производственно-Торговое Предприятие "Инкраслав" Фирмы "Вера, О.О.О. Прешов" | Антисептическая композиция для дезинфекции кожных покровов, способ ее приготовления и полупродукт для ее приготовления |
| US20100158821A1 (en) * | 2008-12-22 | 2010-06-24 | Eastman Chemical Company | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products |
| US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
| US9554994B2 (en) * | 2009-12-16 | 2017-01-31 | Ecolab Usa Inc. | Composition in form of a gel for the virucidal disinfection of mammalian skin |
| US10383894B2 (en) * | 2010-03-17 | 2019-08-20 | Lutran Industries, Inc. | Human medicinal treatment using salt of peroxymonosulfuric acid |
| GB201010256D0 (en) * | 2010-06-18 | 2010-07-21 | Reckitt Benckiser Inc | Germicidal topical compositions |
| FR2976808B1 (fr) * | 2011-06-22 | 2013-06-28 | Urgo Lab | Composition filmogene et son utilisation pour le traitement de l'herpes |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
| US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
| US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
| US10071233B2 (en) * | 2015-05-22 | 2018-09-11 | L'oreal | Point applicator for treating skin conditions |
| US10334853B2 (en) * | 2016-03-29 | 2019-07-02 | Larada Sciences | Compositions and methods for treating ectoparasite infestation |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2054989A (en) * | 1933-12-30 | 1936-09-22 | Us Ind Alcohol Co | Compositions for application to the human skin |
| DE1000367B (de) | 1952-11-17 | 1957-01-10 | Mo Och Domsjoe Ab | Verfahren zur Herstellung von in Wasser und/oder Alkali loeslichen Celluloseaethern |
| US3016328A (en) * | 1961-01-03 | 1962-01-09 | Ethicon Inc | Dialdehyde alcoholic sporicidal composition |
| US4019521A (en) * | 1973-06-06 | 1977-04-26 | Philip Morris Incorporated | Smokable material and method for preparing same |
| US3876771A (en) * | 1973-09-04 | 1975-04-08 | Hallister Inc | Skin protective gel containing polyvinyl methylether or monoisopropyl ester of polyvinyl methylether maleic acid |
| GB1582744A (en) * | 1976-06-04 | 1981-01-14 | Gruenenthal Gmbh | 7h-thiazolo (and 1,3,4-thiadiazolo-)(3,2-a) pyrimidin-7-one-5-carboxylic acids derivatives and medicaments therof |
| SE418686B (sv) * | 1978-03-31 | 1981-06-22 | Landstingens Inkopscentral | Vattenbaserad salva for huddesinfektion innehallande alkohol som desinfektionsmedel |
| GB1593097A (en) * | 1978-05-26 | 1981-07-15 | Fisons Ltd | Pharmaceutical compositions containing a bischromone |
| US4256872A (en) * | 1978-09-26 | 1981-03-17 | Occidental Research Corporation | Process for preparing layered organophosphorus inorganic polymers |
| US4247547A (en) * | 1979-03-19 | 1981-01-27 | Johnson & Johnson | Tretinoin in a gel vehicle for acne treatment |
| US4590214A (en) * | 1980-04-14 | 1986-05-20 | Sepreh, Inc. | Method of treatment for herpes |
| JPS5855411A (ja) * | 1981-09-28 | 1983-04-01 | Nitto Electric Ind Co Ltd | 基剤組成物および外用医薬組成物 |
| US4431633A (en) * | 1982-04-27 | 1984-02-14 | Merck & Co., Inc. | Influenza vaccine |
| DE3430709A1 (de) * | 1984-08-21 | 1986-03-06 | Krüger GmbH & Co KG, 5060 Bergisch Gladbach | Viruzides mittel |
| US5288486A (en) * | 1985-10-28 | 1994-02-22 | Calgon Corporation | Alcohol-based antimicrobial compositions |
| US4671955A (en) * | 1986-03-31 | 1987-06-09 | Victor Palinczar | Waterproof sunscreen compositions |
| FR2613621B1 (fr) * | 1987-04-10 | 1990-06-29 | Roussel Uclaf | Butyl hydroxyanisoles pour utilisation dans le traitement prophylactique des maladies a retro-virus comme agents modificateurs de l'infectivite des retro-virus et produits anti-infectants |
| US5098717A (en) * | 1987-12-09 | 1992-03-24 | Thames Pharmacal Co., Inc. | Method of treatment for pruritus |
| US5013545A (en) * | 1987-12-09 | 1991-05-07 | Thames Pharmacal Co., Inc. | Aqueous gels containing topical medicaments |
| CA1337329C (en) * | 1989-01-31 | 1995-10-17 | Paul L. Simmons | Biodegradable disinfectant |
| US4923875A (en) * | 1989-07-10 | 1990-05-08 | Baker Cummins Pharmaceuticals, Inc. | Method for treatment of mast cell-mediated dermatologic disorders |
| US5331012A (en) * | 1990-07-30 | 1994-07-19 | Riddick Kenneth B | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use |
| SE9003712L (sv) * | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner |
| DE69219470T2 (de) * | 1991-06-20 | 1997-11-06 | Viro Tex Corp | Topisches Präparat zur besseren Heilung von Herpesverletzungen |
| US5376366A (en) | 1992-11-12 | 1994-12-27 | John Petchul | Composition and process for forming isopropyl alcohol gel with water-soluble vinyl polymer neutralizing agent |
| PT751789E (pt) * | 1994-03-21 | 2002-04-29 | Aase Brown Thomsen | Gel para o tratamento de doencas da pele e para desinfeccao da pele |
| US5665751A (en) * | 1995-06-07 | 1997-09-09 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
-
1995
- 1995-03-20 PT PT95928856T patent/PT751789E/pt unknown
- 1995-03-20 JP JP52438095A patent/JP3560977B2/ja not_active Expired - Fee Related
- 1995-03-20 UA UA96103958A patent/UA41989C2/uk unknown
- 1995-03-20 MX MX9604208A patent/MX9604208A/es not_active IP Right Cessation
- 1995-03-20 SK SK1194-96A patent/SK281575B6/sk unknown
- 1995-03-20 DE DE69523745T patent/DE69523745T2/de not_active Expired - Fee Related
- 1995-03-20 CA CA002186045A patent/CA2186045A1/en not_active Abandoned
- 1995-03-20 EP EP95928856A patent/EP0751789B1/de not_active Expired - Lifetime
- 1995-03-20 BR BR9507164A patent/BR9507164A/pt not_active IP Right Cessation
- 1995-03-20 DK DK95928856T patent/DK0751789T3/da active
- 1995-03-20 AU AU21099/95A patent/AU701872B2/en not_active Ceased
- 1995-03-20 KR KR1019960705197A patent/KR100396278B1/ko not_active IP Right Cessation
- 1995-03-20 CN CN95192710A patent/CN1146725A/zh active Pending
- 1995-03-20 WO PCT/EP1995/001025 patent/WO1995025544A1/en active IP Right Grant
- 1995-03-20 HU HU9602583A patent/HUP9774641A2/hu unknown
- 1995-03-20 EE EE9600195A patent/EE03293B1/xx not_active IP Right Cessation
- 1995-03-20 NZ NZ28313595A patent/NZ283135A/xx unknown
- 1995-03-20 RU RU96120210A patent/RU2142273C1/ru not_active IP Right Cessation
- 1995-03-20 US US08/714,162 patent/US5981605A/en not_active Expired - Fee Related
- 1995-03-20 CZ CZ19962723A patent/CZ286758B6/cs not_active IP Right Cessation
- 1995-03-20 PL PL95316651A patent/PL179918B1/pl not_active IP Right Cessation
- 1995-03-20 AT AT95928856T patent/ATE208212T1/de not_active IP Right Cessation
- 1995-03-20 ES ES95928856T patent/ES2168111T3/es not_active Expired - Lifetime
-
1996
- 1996-09-18 FI FI963696A patent/FI963696A/fi not_active IP Right Cessation
- 1996-09-20 NO NO19963971A patent/NO314126B1/no unknown
-
1999
- 1999-10-13 US US09/416,940 patent/US6342537B1/en not_active Expired - Fee Related
- 1999-11-05 CZ CZ19993933A patent/CZ288150B6/cs not_active IP Right Cessation
-
2001
- 2001-12-12 US US10/012,303 patent/US20020086905A1/en not_active Abandoned
-
2002
- 2002-11-04 LV LVP-02-191A patent/LV12951B/en unknown
-
2003
- 2003-08-19 US US10/642,650 patent/US20040054015A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO314126B1 (no) | Farmasöytisk preparat i gelform for behandling av hudsykdommer og for desinfisering av huden, samt anvendelse av en kombinasjon av et polymer-geldannelsesmiddels og en lavere alkanol ved fremstilling av et preparat oganvendelse av enlavere alk | |
| JP7054212B2 (ja) | 有効な創傷ケア処置としての新規高速付着薄膜形成組成物 | |
| DK175632B1 (da) | Tofaseoplösningsmiddelbærersystem | |
| US20020165277A1 (en) | Virucidal compositions | |
| JP5740393B2 (ja) | 皮膚および爪の真菌感染症の局所治療に適した組成物 | |
| US5888523A (en) | Topical non-steroidal anti-inflammatory drug composition | |
| KR20170036058A (ko) | 코 적용을 위한 시네올-함유 조성물 | |
| US20100292333A1 (en) | Compositions suitable for the topical treatment of fungal infections of the skin and nails | |
| EP1372389B1 (de) | Viruzide zusammensetzungen | |
| RU2233151C2 (ru) | Применение тозилхлорамидов для лечения заболеваний кожи и слизистой оболочки | |
| WO2009054992A1 (en) | Antimicrobial compositions comprising docusate | |
| AU2012250489A1 (en) | Avian-based treatment for microbial infections | |
| RU2486905C1 (ru) | Средство для лечения мастита у животных | |
| RU2292198C1 (ru) | Средство лечения грибковых заболеваний кожи широкого спектра действия | |
| KR20230145034A (ko) | 진균 감염의 치료 및/또는 예방용 조성물 | |
| BR102018016079A2 (pt) | Filme polimérico de fibras da cana de açúcar saccharum officinarum l |